Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inno 8
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Inno 8 is an investigational, VHH-based Factor VIIIa mimetic designed to replace or mimic Factor VIII activity for the treatment of haemophilia A. It is described as a novel single-domain antibody recombinant protein with ultrahigh potency, being developed for once-daily oral administration, with both single-ascending-dose and multiple-ascending-dose evaluations in Phase 1 healthy volunteer studies intended to support development in haemophilia A patients.[5][3][1]
- Other names
- Inno 8Inno8Inno-8
02
Targets
Coagulation Factor IXaF10 (Factor Xa)F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on Inno 8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inno 8.